CureVac N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021 - Form 6-K
January 03, 2022 at 04:19 pm EST
Share
CureVac N.V.
Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement
As of
June 30, 2021
CureVac N.V.
Interim Condensed Consolidated Statements of Operations and
Other Comprehensive Income (Loss)
Six months ended June 30,
2020
2021
(in thousands of EUR, except per share amounts)
(unaudited)
Revenue
37,668
32,425
Cost of sales
(5,076
)
(53,156
)
Selling and distribution expenses
(1,009
)
(1,029
)
Research and development expenses
(41,768
)
(236,267
)
General and administrative expenses
(23,725
)
(50,651
)
Other operating income
7,732
45,234
Other operating expenses
(238
)
(214
)
Operating loss
(26,416
)
(263,658
)
Finance income
1,229
7,296
Finance expenses
(10,714
)
(8,065
)
Loss before income tax
(35,901
)
(264,427
)
Income tax benefit/ (expense)
1,760
(1,329
)
Net loss for the period
(34,141
)
(265,756
)
Other comprehensive income:
Foreign currency adjustments
2
(30
)
Total comprehensive loss for the period
(34,139
)
(265,786
)
Net loss per share (basic and diluted)
(0.35
)
(1.44
)
CureVac N.V.
Interim Condensed Consolidated Statements of Financial Position
December 31,
June 30,
(in thousands of EUR)
2020
2021
(unaudited)
Assets
Non-current assets
Intangible assets
14,146
16,196
Property, plant and equipment
66,605
135,577
Right-of-use assets
33,984
32,527
Other assets
6,322
7,454
Deferred tax assets
445
349
Total non-current assets
121,502
192,103
Current assets
Inventories
14,531
62,912
Trade receivables
1,014
2,592
Contract assets
808
2,302
Other financial assets
2,619
40,107
Prepaid expenses and other assets
48,289
145,217
Cash and cash equivalents
1,322,593
1,355,812
Total current assets
1,389,854
1,608,942
Total assets
1,511,356
1,801,045
Equity and liabilities
Equity
Issued capital
21,655
22,425
Capital reserve
1,334,704
1,726,713
Treasury Shares
-
(3,022
)
Accumulated deficit
(645,069
)
(910,825
)
Other comprehensive income
57
27
Total equity
711,347
835,318
Non-current liabilities
Finance liabilities
25,189
26,726
Lease liabilities
26,853
25,825
Contract liabilities
500,061
98,891
Other liabilities
284
284
Total non-current liabilities
552,387
151,726
Current liabilities
Lease liabilities
3,234
3,143
Trade and other payables
21,685
76,569
Other liabilities
64,326
78,602
Income taxes payable
392
204
Contract liabilities
157,985
655,483
Total current liabilities
247,622
814,001
Total liabilities
800,009
965,727
Total equity and liabilities
1,511,356
1,801,045
Attachments
Original Link
Original Document
Permalink
Disclaimer
CureVac NV published this content on 03 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 January 2022 21:18:05 UTC.
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
CUREVAC N.V. 
